ANE 2023 Poster A006

Characterizing Antitumor Response of PARP Inhibitors and Synergy of Docetaxel and PARP Inhibitors in BRCA1/2 Mutant TNBC Breast Cancer PDX Models

Jinxi Wang, Leilei Chen, Likun Zhang, Binchen Mao, Sheng Guo, Rekha Pal, Ludovic Bourre, Jessie J.J. Wang

Crown Bioscience Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127

BRCA1 (BReast CAncer gene 1) and BRCA2 (BReast CAncer gene 2) are tumor suppressor genes that produce proteins which help repair damaged DNA. According to current investigations, 55%–72% of women who inherit a harmful BRCA1 variant and 45%–69% of women who inherit a harmful BRCA2 variant will develop breast cancer by 70–80 years of age.

Even though FDA-approved poly(ADP-ribose) polymerase inhibitors (PARPis), like olaparib or talazoparib, are successful in some BRCA-associated breast cancers, the occurrence of PARPi’s resistance remains a therapeutic challenge. In order to reduce or overcome PARPi resistance, combination strategies with chemo-, targeted- and immuno-therapies are tested both in preclinical and clinical studies.

In this study, we investigated the antitumor response of olaparib and the synergy of docetaxel and olaparib in a cohort of breast cancer PDX models. These models originated from patients with different treatment histories, including primary and metastasis lesions with different BRCA1/2 mutation status.

Download This Poster to Discover:

• Observed synergy and anti-tumor response of docetaxel and olaparib in a cohort of six breast cancer PDX models
  
  
• Breast cancer subtype, clinical diagnosis, patient treatment history, and BRCA1 & BRCA2 mutation details of the breast cancer cohort of PDX models
  
  
• Genomic comparisons of the cohort of breast cancer PDX models to predict which populations may be responsive to docetaxel and olaparib combination treatment

Download the Poster Now!